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Group A Streptococcus (GAS) causes a wide range of human infections, ranging from 
simple pharyngitis to life-threatening necrotizing fasciitis and toxic shock syndrome. A 
globally disseminated clone of M1T1 GAS has been associated with an increase in severe, 
invasive GAS infections in recent decades. The secreted GAS pore-forming toxin strep-
tolysin O (SLO), which induces eukaryotic cell lysis in a cholesterol-dependent manner, 
is highly upregulated in the GAS M1T1 clone during bloodstream dissemination. SLO is 
known to promote GAS resistance to phagocytic clearance by neutrophils, a critical first 
element of host defense against invasive bacterial infection. Here, we examine the role of 
SLO in modulating specific neutrophil functions during their early interaction with GAS. 
We find that SLO at subcytotoxic concentrations and early time points is necessary and 
sufficient to suppress neutrophil oxidative burst, in a manner reversed by free cholesterol 
and anti-SLO blocking antibodies. In addition, SLO at subcytotoxic concentrations 
blocked neutrophil degranulation, interleukin-8 secretion and responsiveness, and 
elaboration of DNA-based neutrophil extracellular traps, cumulatively supporting a key 
role for SLO in GAS resistance to immediate neutrophil killing. A non-toxic SLO derivate 
elicits protective immunity against lethal GAS challenge in a murine infection model. 
We conclude that SLO exerts a novel cytotoxic-independent function at early stages 
of invasive infections (<30 min), contributing to GAS escape from neutrophil clearance.
Keywords: group a Streptococcus, Streptococcus pyogenes, pore-forming toxin, streptolysin O, neutrophils, 
oxidative burst, neutrophil extracellular traps, infection
inTrODUcTiOn
The Gram-positive bacterium group A Streptococcus (GAS; Streptococcus pyogenes) is a leading 
human pathogen ranked among the top 10 causes of infection-associated mortality worldwide 
(1). An estimate of 5–15% of all humans are colonized with GAS, which can cause a wide 
spectrum of infections ranging from self-limiting pharyngitis and impetigo to invasive and 
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life-threatening diseases including streptococcal toxic shock 
syndrome and necrotizing fasciitis (2). Among 700 million 
GAS infections worldwide annually, an estimated 1.8 million 
severe infections occur with a mortality rate as high as 25% (1). 
A commercial vaccine to protect against GAS infections is not 
yet available (3).
The ability of GAS to produce serious disease, sometimes 
in previously healthy children and adults, defines a capacity 
of the organism to resist clearance by frontline elements of the 
host innate immune system, including neutrophils, the most 
abundant circulating leukocytes, which are rapidly recruited 
to sites of bacterial infection (4, 5). GAS express an array of 
virulence factors that allow the bacterium to counteract neu-
trophil processes and molecular effectors of bactericidal activ-
ity (6), including the anti-phagocytic surface hyaluronic acid 
capsule and M protein (7, 8), nuclease-mediated degradation 
of neutrophil extracellular traps (NETs) (9, 10), factors that 
neutralize reactive oxygen species (ROS) (11), and inhibitors 
of neutrophil-derived cationic antimicrobial peptides (12). A 
global increase in invasive GAS infections has been attributed 
to the rise of a single, globally disseminated GAS M1T1 clone 
(13, 14). GAS M1T1 strains can undergo a spontaneous muta-
tion in the two component global regulatory system covR/S 
(also known as csrR/S) in  vivo leading to upregulation of 
capsule, nuclease, and other GAS virulence factors (15, 16), 
and neutrophil resistance may be an important selection pres-
sure for the survival and bloodstream dissemination of these 
mutants (17).
In addition to these “defensive” survival properties, GAS is 
remarkable for its potential to induce the apoptotic cell death of 
neutrophils (18), a phenotype that was subsequently linked to the 
bacterium’s production of the potent pore-forming toxin, strep-
tolysin O (SLO) (19). The slo gene has universally been found 
to be present in the genome of all GAS serotypes and strains, 
and encodes a toxin belonging to the cholesterol-dependent 
cytolysins (CDCs), a family comprising at least 28 members/
bacterial species, including Streptococcus pneumoniae pneumo-
lysin and Listeria monocytogenes listeriolysin O (20). SLO is a 
multi-functional protein with pore-dependent and -independent 
functions (21, 22). SLO is highly expressed by epidemic M1 GAS 
strains (23), and is further upregulated upon covR/S mutation in 
the GAS M1T1 background (15).
In a general sense, SLO toxicity to neutrophils has been 
hypothesized to contribute to GAS bloodstream survival and 
virulence (24, 25). Given the strong bioactivities and high 
expression of this toxin, as well as its prominence in invasive 
M1T1 GAS infection, we undertook a mechanistic analysis of its 
impact on specific neutrophil functions and bactericidal activity. 
We discovered that SLO has the capacity to suppress neutrophil 
oxidative burst and other key neutrophil functions including 
degranulation, directed migration, and formation of NETs, 
together promoting neutrophil resistance. Immunization with 
an inactivated form of SLO (rSLOmut) induced high titers of 
neutralizing IgG and IgM anti-SLO antibodies affording passive 
protection in a mouse model of systemic GAS infection, confirm-
ing its attractiveness as a component of a future multicomponent 
vaccine against this pathogen.
MaTerials anD MeThODs
Bacterial strains
Group A Streptococcus wild-type (WT) strain M1T1 5448 was 
originally isolated from a patient with necrotizing fasciitis and 
toxic shock syndrome (26). The isogenic M1T1 5448 ΔSLO 
mutant and complemented (ΔSLO  +  pSLO) strain were 
described previously (19). The animal-passaged (AP) version 
of the M1T1 GAS parent strain contains a single inactivating 
adenine insertion at the 877-bp position of covS (16). A panel 
of 33 GAS isolates of various M serotypes and clinical associa-
tions was provided from collections of U.S. Centers for Disease 
Control and Prevention (CDC). Additional strains used were S. 
pneumoniae D39, Staphylococcus aureus Newman strain, and 
methicillin-resistant S. aureus (MRSA) TCH1516 WT and its 
isogenic ΔHla mutant. Bacteria were cultivated in Todd–Hewitt 
broth (THB) at 37°C.
isolation of human and Murine 
neutrophils
Neutrophils were isolated from freshly collected whole blood 
of healthy donors under a protocol approved by the University 
of California San Diego (UCSD) Human Research Protections 
Program, using PolyMorphPrep Kit (Fresenius Kabi), as previ-
ously described (27). Mice were sacrificed and blood was col-
lected via terminal cardiac puncture under a protocol approved 
by the UCSD Institutional Animal Care and Use Committee. 
Mouse blood was diluted fivefold in phosphate-buffered saline 
(PBS, Cellgro) and neutrophils were isolated by layers of 
Histopaque-1077 and Histopaque-119 (Sigma). Remaining red 
blood cells (RBCs) were eliminated in lysis buffer (0.15M NH4Cl, 
10 mM KHCO3, 0.1 mM EDTA).
Oxidative Burst assay
Oxidative burst assays were performed as previously described 
(28). Briefly, 2 × 106/mL human or 2 × 105/mL mouse neutro-
phils were loaded with 20 μM 2,7-dichlorofluorescein diacetate 
(DCFH-DA; Fisher) in Hank’s balanced salt solution (HBSS, 
Cellgro) without Ca2+ and Mg2+ and incubated with rotation at 
37°C for 20 min. Neutrophils were resuspended to a density of 
1 × 107 cells/mL and 1 × 106 cells/well were infected at a mul-
tiplicity of infection (MOI) = 1 bacteria/cell and incubated for 
20 min at 37°C/5% CO2. Assays were performed using untreated 
control (control), 25 nM phorbol 12-myristate 13-acetate (PMA, 
Sigma) as positive control, 10 μM diphenyleneiodonium (DPI, 
Sigma) to block generation of ROS, or recombinant SLO protein 
(rSLO), anti-SLO antibody (Abnova), or water-soluble cholesterol 
(Sigma) at the stated concentrations. The fluorescence intensity 
was quantified on a SpectraMax M3 plate reader at 485 nm excita-
tion/520 nm emission using SoftMax Pro software.
neutrophil Killing assays
Neutrophils were isolated as described above, and 1 × 106 cells 
in 100 μL were challenged with bacteria at MOI = 10 bacteria/
cell at 37°C for 30 min with rotation. To pinpoint extracellular 
killing, cells were treated with 10  μg/mL cytochalasin D (cyt. 
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D, Sigma) for 10 min prior to infection to inhibit phagocytosis, 
in the presence or absence of 500  mU/mL desoxyribonuclease 
(DNase, Sigma) to evaluate the contribution of DNA-based NETs 
to bacterial killing. Surviving colony-forming units (CFU) for 
all killing assays were enumerated by Todd-Hewit agar (THA) 
dilution plating. Survival was calculated as the percentage of the 
initial inoculum.
red Blood cell hemolysis assay
Red blood cells were isolated from human blood and super-
natants from bacterial cultures at various growth phases 
OD600 =  0.3–0.7, and tested for hemolysis activity of secreted 
SLO. In these assays, supernatant was incubated with 4  mM 
dithiothreitol (DTT) to stabilize SLO and 0.0004% trypan blue 
at room temperature (RT) for 10 min to inhibit streptolysin S 
activity. RBCs were incubated with bacterial culture supernatant 
with or without anti-SLO antibodies or water-soluble cholesterol 
(Sigma) as indicated for 30 min at 37°C, with PBS (0% hemoly-
sis) or H2O (100% hemolysis) as positive and negative controls. 
Supernatants were collected from assay wells after centrifugation 
at 3000 × g for 15 min, and hemolysis determined by absorbance 
with a SpectraMax M3 plate reader at 541 nm using SoftMax Pro 
software. Each titer was recorded as the point that the hemolysis 
reached half of the 100% RBC lysis (H2O) control.
neutrophil elastase and il-8 release
Neutrophils were infected with bacteria at an MOI of 1 for 30 min 
as described earlier. The release of neutrophil elastase in response 
to bacteria was indirectly determined via the proteolytic activ-
ity of elastase. Cell-free supernatant was incubated with 20 μM 
of peptide substrate N-(Methoxysuccinyl)-Ala-Ala-Pro-Val 
4-nitroanilide (Sigma) for 20  min at RT. The absorbance was 
measured with SpectraMax M3 plate reader at 405 nm for elastase 
using SoftMax Pro software. IL-8 release from neutrophils was 
quantified using the Quantikine ELISA kit (R&D Systems) fol-
lowing the manufacturer’s manual. Briefly, 1 ×  106 neutrophils 
were infected with live GAS WT and ΔSLO at an MOI of 1 for 
60 min and the release of IL-8 was determined via absorbance 
with SpectraMax M3 plate reader at 450 nm using SoftMax Pro 
software.
neutrophil Migration
Migration distance was measured by perfusing neutrophils with 
GAS WT, ΔSLO mutant bacteria at an MOI of 10 and 50. Five nM 
IL-8 was used as a chemotactic stimulus. Migration of individual 
neutrophils was quantified by measuring the distance in microm-
eter after 3 min compared to starting point by microscopy (Zeiss 
Axiolab).
immunostaining of neTs and neT 
Quantification
Neutrophil extracellular trap visualization was performed as 
described previously (29). Briefly, 5 × 106 neutrophils were infected 
with GAS WT and ΔSLO mutant was added at MOI = 1 and incu-
bated for 4 h in 37°C/5% CO2. Cells were fixed with 4% paraform-
aldehyde and stained with anti-myeloperoxidase (MPO) antibody 
(1:300 diluted, Calbiochem) in PBS + 2% bovine serum albumin 
(BSA, Sigma) for 1 h at RT, followed by incubation with goat anti-
rabbit Alexa 488 antibody (1:500 dilution, Life Technologies). 
Cells were counterstained with ProlongGold + 4′,6′-diamidino-
2-phenylindole (DAPI, Invitrogen) and imaged on a fluorescent 
microscope. Representative, randomized images (n =  5) were 
taken for each condition and individual experiment. The ratio of 
NET-releasing cells to non-NET-releasing cells was determined 
as % of total cells releasing NETs.
Transmission electron Microscopy
Neutrophils were infected with GAS WT and ΔSLO mutant for 
4  h at an MOI of 1 and cells were prepared for transmission 
electron microscopy (TEM) as previously described (19, 30). 
Briefly, cells were fixed with 3% formaldehyde, 1.5% glutaral-
dehyde, 0.1M sodium cacodylate trihydrate, 5 mM CaCl2 and 
2.5% sucrose at pH 7.4 buffer for 1 h. Cells were washed three 
times in ice-cold 0.1M sodium cacodylate buffer containing 
2.5% sucrose and fixed cells were incubated with Palade’s OsO4 
by incubation with 1% osmium tetroxide in acetate/veronal 
solution for 1 h on ice. After three washing with acetate/veronal 
solution, the cells were stained and stabilized en bloc in 0.5% 
uranyl acetate with acetate/veronal solution overnight at RT 
in the dark. After one rinse with ddH2O and one rinse with 
ice-cold 50% ethanol, the cells were dehydrated in an ice-cold 
dehydration series of 70, 95, and 100% ethanol for 15 min fol-
lowed by three washes in 100% acetone at RT. Cells were then 
infiltrated in well-mixed Epon-ethanol resin series of three: 3% 
for 7 h, 66% for 7 h, followed by 100% at least overnight with 
agitation at RT. Next, the samples were allowed to polymerize 
in 100% Epon blocks at 60–80°C for a minimum of 48 h. Thin 
sections (70 nm) were examined with FEI Tecnai 12 transmis-
sion electron microscope and images taken with Tietz 214 CCD 
camera. Images were adjusted in brightness and contrast with 
Adobe Photoshop CS version 8.
generation of inactivated rslOmut
Based on the SLO crystal structure (31), a recombinant SLO 
derivate (rSLOmut) with mutated tryptophan residue in the 
membrane-binding loop W535A was generated similarly as 
described (32). Loss of hemolytic activity of the rSLOmut pro-
tein was determined in J774 murine macrophages by TUNEL 
assay as described (19). The rSLOmut protein was cloned by 
overlapping PCR into a pET15b expression vector and expressed 
in Escherichia coli BL21 by induction at OD600 0.6–1.0 with 
1  mM isopropyl-beta-d-thiogalactopyranoside (IPTG) for 4  h. 
Protein purification and quantification by A280 was performed as 
described (19).
slO immunization study
Eight-week-old male CD1 mice (Charles River Laboratories) 
were immunized three times, 2 weeks apart, with recombinant 
SLOmut protein or PBS control, plus adjuvant. The first immu-
nization was done with Freund’s complete adjuvant, and the fol-
lowing two immunizations were done with Freund’s incomplete 
adjuvant. Protein or PBS were mixed with adjuvant 1:1 and 
emulsified, resulting in a final protein concentration of 500 μg/
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mL. Each mouse was injected intraperitonealy (i.p.) with 100 μL 
of the protein/adjuvant emulsified mixture. Mice were infected 
i.p. with 8 × 107 CFU bacteria 2 weeks after the last immunization. 
Survival was monitored daily for 14 days. Anti-SLO IgG and IgM 
antibody titer was measured by ELISA using the serum collected 
3 days before challenging the mice with GAS.
statistical analysis
All data were collected from at least three independent experi-
ments in triplicate. Experiments using neutrophils were per-
formed with a minimum of three different healthy volunteers. 
The data were combined and expressed as mean ± SEM except 
stated differently. All data were analyzed by unpaired Student’s 
t-test using GraphPad Prism version 5.0 (GraphPad Software 
Inc.). P values <0.05 were considered statistically significant.
resUlTs
gas Production of slO suppresses 
neutrophil Oxidative Burst
A select group of Gram-positive human pathogens including 
GAS, S. aureus, and S. pneumoniae are leading causes of inva-
sive, potentially life-threatening infections worldwide (1, 33, 
34). Neutrophils are a critical first line of defense against such 
invading pathogens, and the rapid production of bactericidal 
ROS is key element of their effectiveness. Compared to S. aureus 
and S.  pneumoniae, GAS of the M1 and M3 serotypes elicited 
a reduced level of oxidative burst from freshly isolated human 
neutrophils 20 min post infection (Figure 1A). As each bacterial 
species is replete with pathogen-associated molecular patterns 
(e.g., lipoteichoic acid, peptidoglycan, and formyl peptides) 
to stimulate neutrophil activation, we hypothesized that GAS 
produced factor(s) that suppressed the full host oxidative burst 
potential. By screening a panel of isogenic M1T1 GAS mutants 
lacking defined virulence factors, we identified a higher neu-
trophil oxidative burst in response to a GAS ΔSLO mutant, 
suggesting that the toxin could play a key role in oxidative burst 
suppression (Figure 1B).
Streptolysin O is a well-studied, secreted virulence factor of 
GAS that induces apoptosis in neutrophils and macrophages at 
later time points (~4 h) (19). We, thus, focused the aim of the 
current study to investigate the role of SLO in the early GAS–
neutrophil interaction (<30  min) independent of cell death. 
Incubation of human neutrophils with GAS WT or ΔSLO mutant 
at MOI of 1, 10, or 50 bacteria/cell for 30 min did not produce cell 
death as assessed by LDH release (Figure S1A in Supplementary 
Material) or Live–Dead staining (Figures S1B,C in Supplementary 
Material). Complementation of the ΔSLO mutant with the slo 
gene expressed on a plasmid vector (ΔSLO +  pSLO) restored 
the WT phenotype confirming that SLO dampens the neutrophil 
ROS response (Figure  1C). Additionally, purified recombinant 
SLO (rSLO) protein was sufficient to reduce the oxidative burst 
in neutrophils in a dose-dependent manner to the levels of the 
untreated control (Figure 1D). Oxidative burst suppression was 
not a universal property of bacterial pore-forming toxins, as live 
methicillin-resistant S. aureus (MRSA) USA300 producing the 
pore-forming virulence factor α-hemolysin (Hla) did not differ 
from an isogenic ΔHla mutant in elicitation of neutrophil ROS 
(Figure S2A in Supplementary Material), nor did recombinant 
Hla toxin at concentrations between 10 and 1000 ng/mL modu-
late oxidative burst (Figure S2B in Supplementary Material).
As ROS production is an important bactericidal effector of 
neutrophils, we confirmed the overall effect of SLO on neutrophil 
bacterial killing. The ΔSLO mutant was significantly more sus-
ceptible to rapid neutrophil killing after 30 min of infection than 
the M1T1 GAS parent strain, and WT resistance was restored in 
the complemented mutant (Figure 1E).
gas M1 serotype and covRS Mutation are 
associated with higher slO activity
An increase in the production of SLO played a key role in the 
evolution of the globally disseminated M1T1 epidemic clone 
responsible for GAS infections of increased frequency and sever-
ity (13, 14, 23). Analysis of 33 clinical isolates obtained from the 
U.S. Center for Disease Control and Prevention (CDC) revealed 
a higher median hemolytic activity of M1 serotypes compared 
to non-M1 serotypes (Figure 2A). In this study, we utilized GAS 
strain 5448, a representative of the globally disseminated M1T1 
clone, which is the most frequently isolated clone from patients 
suffering invasive infections (35, 36). During invasive infections 
in humans, M1T1 GAS (15); and isolates of certain additional 
serotypes (37) undergo spontaneous mutations in the CovRS 
regulator, leading to upregulation of virulence factors including 
SLO and hyaluronic acid capsule, coupled with loss of cysteine 
protease SpeB expression, which can degrade SLO during sta-
tionary phase (38). This “genetic switch” is recapitulated by AP 
of M1T1 GAS in mice (15, 38). Consistent with this model, we 
found that the SLO activity of WT M1T1 GAS is maximal in log-
phase (OD600 0.4–0.6) and declines in stationary phase, while its 
expression is markedly increased in the AP strain bearing a covS 
mutation, remaining high through late-log phase and stationary 
phase due to SpeB inactivation (Figure 2B).
inhibitors of slO activity increase the 
Oxidative Burst response of neutrophils 
to gas
To confirm a key role of SLO in suppression of neutrophil 
oxidative burst, we utilized anti-SLO neutralizing antibodies 
and water-soluble cholesterol, a known inhibitor of SLO activ-
ity (39). Dose-dependent activity of each inhibitor against 
SLO was confirmed by complete ablation of hemolytic activity 
(Figure 3A). Both anti-SLO antibodies and cholesterol reversed 
the suppressive effect of SLO on neutrophil oxidative burst in 
dose-dependent manners (Figures 3B,C). Interestingly, delayed 
administration of cholesterol to neutrophils 30 min after expo-
sure to WT GAS restored oxidative burst expression as measured 
at 60 min (Figure 3D), indicating the effects of the toxin are at 
least partially reversible upon SLO inhibition. When the phar-
macological NADPH oxidase inhibitor, DPI was used to block 
neutrophil ROS generation (40), the survival difference between 
the WT and ΔSLO mutant GAS strains was no longer observed 
(Figure 3E); DPI treatment enhanced survival of both WT and 
FigUre 1 | group a Streptococcus slO suppresses neutrophil oxidative burst. (a) GAS WT serotype M1 and M3 suppress oxidative burst response in 
human neutrophils compared to representative WT strains of Streptococcus pneumoniae (D39) and Staphylococcus aureus (Newman) and media only control. 
(B) An isogenic GAS ΔSLO mutant fails to suppress oxidative burst in neutrophils compared to isogenic ΔM1, ΔSpeB, ΔNAD, and ΔSLS mutants and GAS WT. 
(c) The complemented GAS ΔSLO mutant (ΔSLO + pSLO) restores the suppression of oxidative burst. (D) Recombinant, active SLO protein suppresses oxidative 
burst in a dose-dependent manner in PMA-stimulated neutrophils, including media alone as a negative control. (e) SLO protects against killing by neutrophils at an 
MOI of 10 at 30 min post infection. Results are given in average ± SEM and analyzed by Student’s t-test (n.s., not significant).
FigUre 2 | streptolysin O activity is enhanced in gas M1 serotype and further enhanced after aP of gas M1T1 clone. (a) Thirty-three clinical GAS 
isolates from the CDC were grouped into M1 serotype and non-M1 serotypes, where M1 serotypes including M1 5448 show increased hemolytic activity compared 
to non-M1 serotypes. (B) Hemolytic activity of SLO in GAS WT peaks in log-phase, whereas in an AP strain, M1 is elevated and reaches maximal hemolytic activity 
OD600 ≥ 0.5.
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pore-forming virulence factor α-hemolysin (Hla) did not differ 
from an isogenic ΔHla mutant in elicitation of neutrophil ROS 
(Figure S2A in Supplementary Material), nor did recombinant 
Hla toxin at concentrations between 10 and 1000 ng/mL modu-
late oxidative burst (Figure S2B in Supplementary Material).
As ROS production is an important bactericidal effector of 
neutrophils, we confirmed the overall effect of SLO on neutrophil 
bacterial killing. The ΔSLO mutant was significantly more sus-
ceptible to rapid neutrophil killing after 30 min of infection than 
the M1T1 GAS parent strain, and WT resistance was restored in 
the complemented mutant (Figure 1E).
gas M1 serotype and covRS Mutation are 
associated with higher slO activity
An increase in the production of SLO played a key role in the 
evolution of the globally disseminated M1T1 epidemic clone 
responsible for GAS infections of increased frequency and sever-
ity (13, 14, 23). Analysis of 33 clinical isolates obtained from the 
U.S. Center for Disease Control and Prevention (CDC) revealed 
a higher median hemolytic activity of M1 serotypes compared 
to non-M1 serotypes (Figure 2A). In this study, we utilized GAS 
strain 5448, a representative of the globally disseminated M1T1 
clone, which is the most frequently isolated clone from patients 
suffering invasive infections (35, 36). During invasive infections 
in humans, M1T1 GAS (15); and isolates of certain additional 
serotypes (37) undergo spontaneous mutations in the CovRS 
regulator, leading to upregulation of virulence factors including 
SLO and hyaluronic acid capsule, coupled with loss of cysteine 
protease SpeB expression, which can degrade SLO during sta-
tionary phase (38). This “genetic switch” is recapitulated by AP 
of M1T1 GAS in mice (15, 38). Consistent with this model, we 
found that the SLO activity of WT M1T1 GAS is maximal in log-
phase (OD600 0.4–0.6) and declines in stationary phase, while its 
expression is markedly increased in the AP strain bearing a covS 
mutation, remaining high through late-log phase and stationary 
phase due to SpeB inactivation (Figure 2B).
inhibitors of slO activity increase the 
Oxidative Burst response of neutrophils 
to gas
To confirm a key role of SLO in suppression of neutrophil 
oxidative burst, we utilized anti-SLO neutralizing antibodies 
and water-soluble cholesterol, a known inhibitor of SLO activ-
ity (39). Dose-dependent activity of each inhibitor against 
SLO was confirmed by complete ablation of hemolytic activity 
(Figure 3A). Both anti-SLO antibodies and cholesterol reversed 
the suppressive effect of SLO on neutrophil oxidative burst in 
dose-dependent manners (Figures 3B,C). Interestingly, delayed 
administration of cholesterol to neutrophils 30 min after expo-
sure to WT GAS restored oxidative burst expression as measured 
at 60 min (Figure 3D), indicating the effects of the toxin are at 
least partially reversible upon SLO inhibition. When the phar-
macological NADPH oxidase inhibitor, DPI was used to block 
neutrophil ROS generation (40), the survival difference between 
the WT and ΔSLO mutant GAS strains was no longer observed 
(Figure 3E); DPI treatment enhanced survival of both WT and 
FigUre 1 | group a Streptococcus slO suppresses neutrophil oxidative burst. (a) GAS WT serotype M1 and M3 suppress oxidative burst response in 
human neutrophils compared to representative WT strains of Streptococcus pneumoniae (D39) and Staphylococcus aureus (Newman) and media only control. 
(B) An isogenic GAS ΔSLO mutant fails to suppress oxidative burst in neutrophils compared to isogenic ΔM1, ΔSpeB, ΔNAD, and ΔSLS mutants and GAS WT. 
(c) The complemented GAS ΔSLO mutant (ΔSLO + pSLO) restores the suppression of oxidative burst. (D) Recombinant, active SLO protein suppresses oxidative 
burst in a dose-dependent manner in PMA-stimulated neutrophils, including media alone as a negative control. (e) SLO protects against killing by neutrophils at an 
MOI of 10 at 30 min post infection. Results are given in average ± SEM and analyzed by Student’s t-test (n.s., not significant).
FigUre 3 | inhibition of slO reverses the suppression of oxidative burst. (a) Anti-SLO antibodies and water-soluble cholesterol block hemolytic activity of 
SLO in a dose-dependent manner compared to control without inhibitor. (B) Inhibition of SLO with anti-SLO blocking antibodies or (c) cholesterol prevents 
suppression of oxidative burst in neutrophils in WT GAS with no effect on ΔSLO mutant or media only control 20 min post infection. (D) Oxidative burst in 
neutrophils infected with bacteria was monitored over a 60 min time course and cholesterol (cho) added after 30 min reversed the suppression by SLO. Effect of 
pharmacological inhibition of NADPH oxidase activity by DPI compared to untreated control in response to live GAS WT and ΔSLO mutant on (e) neutrophil 
oxidative burst and (F) neutrophil killing. Results are given in average ± SEM and analyzed by Student’s t-test (n.s., not significant).
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ΔSLO strains, demonstrating that ROS contributes to neutrophil 
killing of GAS (Figure 3F).
slO suppresses neutrophil 
Degranulation and il-8 release/
responsiveness
Reactive oxygen species have been implicated in the activation 
of neutrophil granule proteases including elastase (41, 42). GAS 
suppressed the degranulation of neutrophils in a SLO-dependent 
manner as quantified by elastase release into the supernatant 
(Figure 4A). Activated neutrophils themselves are an important 
source of chemokine interleukin-8 (IL-8), the release of which 
recruits additional neutrophils to the site of inflammation or 
infection (43). After 60 min bacterial coincubation, we observed 
a clear reduction in IL-8 secretion by neutrophils exposed to WT 
GAS compared to the ΔSLO mutant (Figure  4B). Finally, the 
mean distance of neutrophil migration over 3 min in response to 
IL-8 as stimulus was significantly reduced in neutrophils exposed 
to WT GAS compared to those exposed to the ΔSLO mutant 
FigUre 4 | streptolysin O inhibits neutrophil degranulation and il-8 release/responsiveness. (a) Neutrophil degranulation was determined by elastase 
release upon infection with live GAS WT, ΔSLO mutant, complemented bacteria and media only control, as quantified by ELISA. (B) SLO prevents IL-8 release from 
infected neutrophils compared to ΔSLO mutant bacteria and media only control as quantified by ELISA. (c) SLO inhibits neutrophil migration in MOI-dependent 
manner in contrast to ΔSLO mutant bacteria and media only control as measured by microscopic analysis. Results are given in average ± SEM and analyzed by 
Student’s t-test (n.s., not significant).
FigUre 5 | streptolysin O inhibits neT formation and extracellular killing. (a) Representative images from NET induction with GAS are shown by 
immunofluorescence (IF) and transmission electron microscopy (TEM) for untreated control [white arrows = multi-lobulated nuclei; white arrowheads = granules; 
white arrows = multi-lobulated nuclei], GAS WT [asterisk = decondensed chromatin; arrowhead = disintegrated nuclear envelope; arrow = disrupted nuclear 
membrane; asterisk = decondensation of chromatin; arrowhead = disintegrated nuclear envelope; arrow = disrupted cell membrane] and ΔSLO mutant 
[arrow = dilated space between inner and outer membrane; arrowhead = cytoplasmic protrusions and vacuolization; white arrowhead = phagocytosed bacteria; 
asterisk = dissolved membrane and DNA; arrowhead = vesicles of globular proteins; arrow = fibrous DNA strands; asterisk = dissolved membrane], bar = 5 μm 
TEM. (B) SLO suppresses NET formation as quantified for GAS WT, ΔSLO mutant and media only control by IF. (c) Extracellular killing in the presence of 
cytochalasin D of GAS WT, ΔSLO and complemented strain shows that SLO to protect against killing in the presence/absence of DNase control to degrade NETs. 
Results are given in average ± SEM and analyzed by Student’s t-test (n.s., not significant).
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(Figure 4C). Thus, SLO production by GAS impairs neutrophil 
IL-8 release and their activation and migratory responses to the 
chemokine.
slO inhibits neutrophil extracellular Trap 
Formation
Another critical innate immune function from neutrophils 
dependent on oxidative burst activity is NET formation, a special-
ized cell death process in which the nuclear DNA, embedded with 
antimicrobial histones and proteins, is released to ensnare and 
kill bacteria at tissue foci of infection (44, 45). Neutrophils were 
incubated with GAS WT and ΔSLO mutant at MOI of 1 bacteria/
cell for 4 h then stained with antibodies against myeloperoxidase 
(MPO), the most abundant neutrophil granule protein that colo-
calizes within NETs (46). GAS SLO expression inhibited NETosis 
indicated by dissolved cell membranes and fibrous, extracellular 
DNA strands as determined by TEM and immunofluorescence 
(IF) microscopy (Figure 5A). The percentage of NET-releasing 
FigUre 6 | immunization with inactivated rslOmut protects against gas systemic infection. SLO suppresses the oxidative burst in mouse neutrophils 
with (a) live GAS WT compared to ΔSLO mutant or (B) rSLO protein after PMA-stimulation including media alone as control. Serum from rSLOmut-immunized mice 
inhibits SLO suppression of neutrophil oxidative burst from live bacteria (c). Immunization of mice with rSLOmut protein Vs mock prevents mortality of mice 
challenged with GAS WT in systemic infection model (D). Results are shown as ±SEM from a minimum of three independent experiments. Data were analyzed by 
Student’s t-test.
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neutrophils was quantified by counting random IF microscopy 
fields (Figure  5B). M1T1 GAS strains also produce a nuclease 
(Sda1) that degrades the DNA backbone of NETs (9, 10). We con-
firmed that the GAS WT and ΔSLO mutant did not differ in their 
nuclease activity (Figure S3 in Supplementary Material). When 
neutrophils were treated with cytochalasin D to block phagocytic 
uptake of bacteria, survival of the GAS WT and complemented 
strain was greater than the survival of the ΔSLO mutant, differ-
ences that were abolished by DNase treatment (Figure 5C). This 
indicates that a DNA-dependent, extracellular killing process 
contributes to the neutrophil resistance phenotype provided by 
SLO expression.
inactivated slO as a Protective Vaccine 
antigen In vivo
Streptolysin O is a potent toxin that triggers cell apoptosis in vivo 
(47), and deletion of SLO from highly hemolytic M1 and M3 
GAS strains (Figure  2A) has previously been associated with 
loss of virulence in murine models of systemic infection (19, 
48). Potentially, due to GAS being a human-adapted pathogen, 
the oxidative burst response of human neutrophils was more 
robust than that of mouse neutrophils; nevertheless, we found 
a similar effect wherein murine neutrophil ROS production was 
significantly reduced upon exposure to WT GAS compared to 
the ΔSLO mutant (Figure  6A). Recombinant SLO also sup-
pressed the oxidative burst response of PMA-stimulated murine 
neutrophils (Figure  6B). Native SLO may be a poor vaccine 
candidate because of its high cell toxicity, but strategies exist to 
mutate the cell-binding domain to create a toxoid SLO protein 
(rSLOmut) (32). Mice were immunized three times 2 weeks apart 
with rSLOmut, and a significant response in anti-SLO IgG and 
IgM antibodies was documented in serum by ELISA (Figure S4 in 
Supplementary Material). The post-immune antisera was found 
to reverse the inhibitory effect of SLO on the oxidative burst 
of mouse neutrophils (Figure  6C), demonstrating the capacity 
of the antibodies to block SLO neutrophil suppression. Mice 
immunized with rSLOmut were significantly protected against 
lethal systemic challenge with WT GAS M1 strain (Figure 6D), 
further supporting the inactivated SLO antigen as an attractive 
component for future multivalent GAS vaccines.
DiscUssiOn
Group A Streptococcus remains one of the top 10 causes of 
infection-related morbidity and mortality worldwide (1). The aim 
of this study was to investigate the mechanisms GAS employs at 
early time points of infection (<30 min) to resist innate immune 
clearance by neutrophils. Generation of ROS upon bacterial 
encounter is an immediate neutrophil response to kill pathogens 
and to activate inflammatory signaling to recruit immune cells 
to the site of infection. As GAS is a non-pigmented and catalase-
negative bacterium, it is dependent on alternative strategies to 
circumvent hostile ROS-rich host environments (11). Here, 
we identify SLO as the major bacterial factor responsible for 
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suppressing the oxidative burst in neutrophils, facilitating GAS 
escape from innate immune killing. Previously, a study using 
the recombinant Mac-1/IdeS protease from GAS proposed that 
this virulence factor could be suppressing ROS production (49). 
However, physiological levels of Mac-1/IdeS from live bacteria 
had no effect on ROS response or virulence (50). To the best of 
our knowledge, SLO is the first GAS virulence factor shown to be 
necessary and sufficient for suppressing production of bacteri-
cidal ROS, thereby subverting neutrophil ROS-dependent killing. 
Our study shows that SLO produced by live bacteria as well as 
recombinant SLO protein is necessary and sufficient to modulate 
innate immune cell functions at early time points of infection. 
A specific suppression of oxidative burst from neutrophils by 
SLO was further demonstrated by using specific inhibitor of SLO 
activity, cholesterol, or anti-SLO blocking antibodies.
Streptolysin O, PLY, LLO, and PFO, all belong to the same 
family of CDCs (20). Interestingly, neither the pore-forming 
staphylococcal α-hemolysin nor its production from live S. aureus 
had a similar effect on oxidative burst in neutrophils, suggesting 
a specific unique role of SLO and related toxins that is not a 
general consequence of membrane perturbation and disruption. 
Recently, LLO and PFO have been shown to suppress oxidative 
burst in murine macrophages by preventing the localization of 
NADPH oxidase with the phagosome (51).
To extend the analysis of SLO in suppressing neutrophil 
functions, we investigated its role in additional ROS-dependent 
functions critical in clearance of bacterial pathogens. The pro-
duction of ROS is linked to degranulation and the elaboration of 
extracellular traps, which is a critical function for entrapment and 
extracellular killing of bacteria (44). Our findings show that SLO 
prevents the release of IL-8 and elastase from neutrophils and 
blocks the formation of NETs. In our study, we confirmed that 
SLO contributes to resistance to an extracellular killing mecha-
nism that is DNA-dependent. The hyperinvasive M1T1 GAS 
clone expresses a potent phage encoded nuclease (Sda1) that, like 
SLO, is upregulated on covR/S mutations arising in vivo under 
innate immune selection (15, 16). Thus, GAS has evolved a dual-
pronged approach to both reduce the production of NETs, and to 
further dissolve NETs that are established, effectively neutralizing 
this arm of innate immunity.
In summary, we described a number of incapacitating effects 
of SLO on neutrophil function that act rapidly to suppress neu-
trophil function in advance of the toxin’s ultimate and previously 
established role in triggering cell death pathways in the phagocyte. 
The importance of these virulence phenotypes is underscored by 
the protective effect of active immunization with an rSLOmut 
toxoid vaccine against invasive GAS infection. As SLO is present 
in all GAS serotypes and strains, our findings support proposals 
(3, 32) to include inactivated SLO toxoid as a component of a mul-
ticomponent vaccine against a leading human pathogen, GAS.
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